For millions of Americans managing diabetes, a new option may soon be on pharmacy shelves. Sunshine Lake Pharma, a leading biopharmaceutical firm on the Chinese mainland, announced this week that its long‑acting insulin glargine injection, marketed as Langlara, has received approval from the United States Food and Drug Administration (FDA). The green light makes the company the first from the Chinese mainland to win such clearance, a milestone that could reshape the competitive landscape of the U.S. insulin market.
Langlara is only the fourth insulin glargine product to enter the United States, joining the offerings of global giants Novo Nordisk, Sanofi and Eli Lilly. The FDA designation of interchangeability—reserved for biosimilars that meet the highest standards—means pharmacists can substitute Langlara for the reference product without a new prescription, a feature that could accelerate its uptake among clinicians and patients.
The United States is the world’s largest insulin market, with annual spending surpassing $400 billion and accounting for nearly 80 % of global sales. Sunshine Lake Pharma has already secured an initial order of at least 18 million vials from its U.S. partner, Lannett, with deliveries scheduled over the next 18 months. The company’s production capacity currently stands at more than 100 million vials per year, with plans to expand to 180 million vials as demand grows.
Sunshine Lake Pharma began building its insulin portfolio in 2008, investing more than 2 billion yuan (about $280 million) in research and manufacturing. Its strategy has been to first establish a presence in emerging markets—its products have already been approved in the United Arab Emirates, Algeria and Mali, and it operates across the Middle East, Latin America and Southeast Asia. The FDA nod is expected to fast‑track entries into additional large markets such as Brazil, Argentina, Indonesia and Türkiye, while another insulin product awaits a U.S. decision in 2028.
Industry observers note that as major insulin manufacturers face mounting pressure to lower prices in the United States, lower‑cost alternatives like Langlara could capture a growing share of the market, offering relief to patients and payers alike.
Reference(s):
Chinese insulin breaks into US market as new drug secures FDA approval
cgtn.com
